Leerink Maintains Outperform on Tesaro (TSRO) Boosts PT To $152, Alters Sales Forecast For Niraparib

Leerink Partners Outperform Tesaro (NASDAQ: TSRO) price target of $152.00 (from $115.00).

Leerink analyst Seamus Fernandez comments "In our view, the strong data from niraparib's NOVA trial, along with the lack of an expected FDA panel, should result in a broad label in the second-line or greater (2L+) ovarian cancer maintenance setting. Ongoing niraparib trials in breast cancer and front-line (1L) ovarian cancer maintenance, as well as the company's IO platform, are additional pot'l drivers of upside for the stock. Further, we see TSRO as an attractive takeout target, and our P/S analysis of recent M&A transactions supports an acquisition price up to >$170/shr based on consensus sales forecasts."

Fernandez also adjusts his 2026 WW niraparib sales forecast in ovarian and breast cancer from ~$1.7B to $~2.0B, saying:

"Changes to our niraparib model include: (1) the risk-adjusted addition of gBRCA-negative/HRD-negative 1L maintenance ovarian cancer patients based on the expansion of the PRIMA trial; (2) increases in the probability of success and penetration estimates for the drug in gBRCA-negative/HRD-negative 2L maintenance ovarian cancer patients; (3) the inclusion of royalties and milestone payments from Janssen (JNJ, OP) for prostate cancer; and (4) an increase in the net price of niraparib based on the recent launch price of CLVS's (NR) Rubraca (rucaparib).

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $143.58 Friday.

You May Also Be Interested In

• Boston Scientific (BSX) PT Raised to $83 at Stifel
• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• Amphenol (APH) PT Raised to $130 at Evercore ISI, Remains Top Pick